The PhysioMimix® Bioavailability Assay Kit: Human 18, the only in vitro bioavailability tool available for profiling human drug bioavailability, is set to transform how CROs, pharmaceutical, and biotech companies approach preclinical ADME testing.

The all-in-one kit facilitates effortless Organ-on-a-Chip adoption into existing workflows, bridging the knowledge gap between in vitro and in vivo studies, to enhance lead optimization and preclinical testing pipelines ahead of in vivo animal and first-in-human trials.

Why Bioavailability Matters

Understanding a drug’s bioavailability is crucial for determining its therapeutic efficacy and safety. Accurate bioavailability assessments inform optimal dosing regimens and are essential for regulatory approvals prior to clinical trials. Traditional methods, including isolated in vitro assays and animal studies, often fall short in predicting human responses due to assay limitations and physiological differences.

The PhysioMimix^® Advantage

Our Bioavailability assay kit: Human 18 leverages the PhysioMimix Gut/Liver-on-a-chip model  to offer a unique solution that combined abilities of the:

• RepliGut^®– Planar Jejunum model: Developed by Altis Biosystems, this model accurately mimics the human intestinal barrier, providing a more physiologically relevant alternative to traditional Caco-2 assays.
• PhysioMimix^® Liver-on-a-chip: Our FDA-recognized liver model maintains high metabolic activity, closely replicating human liver functions for more accurate drug metabolism studies.

By fluidically linking these two models, the kit allows for simultaneous simulation of oral and intravenous drug dosing within a single experiment. This interconnected system enables assessment of intestinal absorption, intestinal metabolism, and hepatic clearance concurrently, offering a more comprehensive understanding of a drug’s bioavailability in humans.

To learn more, visit the Bioavailability assay kit: Human 18 product page